keyword
MENU ▼
Read by QxMD icon Read
search

Protocol chemotherapy for lung cancer

keyword
https://www.readbyqxmd.com/read/29666135/study-protocol-for-the-saron-trial-a-multicentre-randomised-controlled-phase-iii-trial-comparing-the-addition-of-stereotactic-ablative-radiotherapy-and-radical-radiotherapy-with-standard-chemotherapy-alone-for-oligometastatic-non-small-cell-lung-cancer
#1
John Conibear, Brendan Chia, Yenting Ngai, Andrew Tom Bates, Nicholas Counsell, Rushil Patel, David Eaton, Corinne Faivre-Finn, John Fenwick, Martin Forster, Gerard G Hanna, Susan Harden, Philip Mayles, Syed Moinuddin, David Landau
INTRODUCTION: Following growing evidence to support the safety, local control (LC) and potential improvement in overall survival (OS) in patients with oligometastatic non-small cell lung cancer (NSCLC) that have been treated with local ablative therapy such as stereotactic ablative radiotherapy (SABR) and stereotactic radiosurgery (SRS), we initiate the SARON trial to investigate the impact and feasibility of adding SABR/SRS and radical radiotherapy (RRT) following standard chemotherapy on OS...
April 17, 2018: BMJ Open
https://www.readbyqxmd.com/read/29614265/pharmacokinetic-pharmacodynamic-modeling-of-combination-chemotherapy-for-lung-cancer
#2
Louis T Curtis, Victor H van Berkel, Hermann B Frieboes
Chemotherapy for non-small cell lung cancer (NSCLC) typically involves a doublet regimen for a number of cycles. For any particular patient, a course of treatment is usually chosen from a large number of combinational protocols with drugs in concomitant or sequential administration. In spite of newer drugs and protocols, half of patients with early disease will live less than five years and 95% of those with advanced disease survive for less than one year. Here, we apply mathematical modeling to simulate tumor response to multiple drug regimens, with the capability to assess maximum tolerated dose (MTD) as well as metronomic drug administration...
March 31, 2018: Journal of Theoretical Biology
https://www.readbyqxmd.com/read/29599365/feasibility-study-of-sequentially-alternating-egfr-tkis-and-chemotherapy-for-patients-with-non-small-cell-lung-cancer
#3
Yoshizumi Takemura, Yusuke Chihara, Yoshie Morimoto, Keiko Tanimura, Tatsuya Imabayashi, Yurie Seko, Yoshiko Kaneko, Koji Date, Mikio Ueda, Taichiro Arimoto, Yoshinobu Iwasaki, Koichi Takayama
BACKGROUND/AIM: The purpose of this trial was to evaluate the feasibility and efficacy of alternating platinum-based doublet chemotherapy with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with EGFR-mutant non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Chemotherapy-naive patients with advanced NSCLC harboring an EGFR mutation were enrolled. All patients underwent induction chemotherapy by sequentially alternating pemetrexed/cisplatin/bevacizumab and EGFR-TKIs followed by maintenance therapy with pemetrexed/bevacizumab and EGFR-TKIs...
April 2018: Anticancer Research
https://www.readbyqxmd.com/read/29572004/phase-ii-trial-of-preoperative-pemetrexed-plus-carboplatin-in-patients-with-stage-ib-iii-nonsquamous-non-small-cell-lung-cancer-nsclc
#4
John D Hainsworth, David M Waterhouse, Kent C Shih, Ralph V Boccia, Victor M Priego, Michael J McCleod, Fred J Kudrik, Reed Brian Mitchell, Howard A Burris, F Anthony Greco, David R Spigel
OBJECTIVES: The combination of pemetrexed and carboplatin is a standard first-line treatment for patients with advanced NSCLC. In this pilot phase II trial, we evaluated the feasibility of using pemetrexed and carboplatin as neoadjuvant therapy, prior to definitive surgical resection, for patients with localized NSCLC. PATIENTS AND METHODS: Patients with potentially resectable, previously untreated, clinical stage IB-III, nonsquamous NSCLC were eligible for this trial...
April 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29555258/modified-xeliri-capecitabine-plus-irinotecan-versus-folfiri-leucovorin-fluorouracil-and-irinotecan-both-either-with-or-without-bevacizumab-as-second-line-therapy-for-metastatic-colorectal-cancer-axept-a-multicentre-open-label-randomised-non-inferiority-phase
#5
Rui-Hua Xu, Kei Muro, Satoshi Morita, Satoru Iwasa, Sae Won Han, Wei Wang, Masahito Kotaka, Masato Nakamura, Joong Bae Ahn, Yan-Hong Deng, Takeshi Kato, Sang-Hee Cho, Yi Ba, Hiroshi Matsuoka, Keun-Wook Lee, Tao Zhang, Yasuhide Yamada, Junichi Sakamoto, Young Suk Park, Tae Won Kim
BACKGROUND: Studies of a modified XELIRI (mXELIRI; capecitabine plus irinotecan) regimen suggest promising efficacy and tolerability profiles in the first-line and second-line settings. Therefore, we aimed to compare the efficacy and safety of the mXELIRI regimen with that of standard FOLFIRI (leucovorin, fluorouracil, and irinotecan), with or without bevacizumab in both regimens, as a second-line therapy for metastatic colorectal cancer. METHODS: We did a multicentre, open-label, randomised, non-inferiority, phase 3 trial...
March 16, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29450591/occurrence-of-pneumonitis-following-radiotherapy-of-breast-cancer-a-prospective-study
#6
Danijela Vasiljevic, Christoph Arnold, David Neuman, Katharina Fink, Marina Popovscaia, Irma Kvitsaridze, Meinhard Nevinny-Stickel, Markus Glatzer, Peter Lukas, Thomas Seppi
AIM: of this study is to determine the temporal resolution of therapy-induced pneumonitis, and to assess promoting factors in adjuvant treated patients with unilateral mammacarcinoma. PATIENTS AND METHODS: A total of 100 post-surgery patients were recruited. The cohort was treated by 2 field radiotherapy (2FRT; breast and chest wall, N = 75), 3 field radiotherapy (3FRT; + supraclavicular lymphatic region, N = 8), or with 4 field radiotherapy (4FRT; + parasternal lymphatic region, N = 17)...
February 15, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29424199/primary-synchronous-small-and-non-small-cell-lung-cancer-in-the-same-lung-lobe-a-case-report
#7
Anton Dzian, Fúčela Ivan, Huťka Zdenko, Szépe Peter
Synchronous multiple primary lung cancer (SMPLC) means tumours present at the same time, which are separate and have different histology. We present the case of a 66-year-old patient with a combination of small-cell lung carcinoma (SCLC) with adenocarcinoma in the same lobe with metastasis of SCLC in the mediastinal lymph node. This is a rare case. We performed a standard left upper video-assisted thoracoscopic lobectomy with mediastinal lymphadenectomy and adjuvant therapy targeted to SCLC was administered...
December 14, 2017: Monaldi Archives for Chest Disease, Archivio Monaldi Per le Malattie del Torace
https://www.readbyqxmd.com/read/29357823/chemotherapy-weakly-contributes-to-predicted-neoantigen-expression-in-ovarian-cancer
#8
Timothy O'Donnell, Elizabeth L Christie, Arun Ahuja, Jacqueline Buros, B Arman Aksoy, David D L Bowtell, Alexandra Snyder, Jeff Hammerbacher
BACKGROUND: Patients with highly mutated tumors, such as melanoma or smoking-related lung cancer, have higher rates of response to immune checkpoint blockade therapy, perhaps due to increased neoantigen expression. Many chemotherapies including platinum compounds are known to be mutagenic, but the impact of standard treatment protocols on mutational burden and resulting neoantigen expression in most human cancers is unknown. METHODS: We sought to quantify the effect of chemotherapy treatment on computationally predicted neoantigen expression for high grade serous ovarian carcinoma patients enrolled in the Australian Ovarian Cancer Study...
January 22, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29316288/carboplatin-plus-pemetrexed-for-the-elderly-incurable-chemo-naive-nonsquamous-non-small-cell-lung-cancer-meta-analysis
#9
Masaru Ito, Nobuyuki Horita, Akimichi Nagashima, Takeshi Kaneko
AIM: In some developed countries, a proportion of nonsquamous non-small cell lung cancer (NSq NSCLC) patients are aged over 70 years when they are diagnosed. However, evidence of lung cancer chemotherapy usually comes from randomized controlled trials that only recruit younger patients with good performance status. In daily practice, less-toxic carboplatin + pemetrexed regimen is often used for elderly patients, although this regimen is not sufficiently supported by rigid evidence for elderly cases...
January 8, 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29116741/high-performance-poly-lactic-co-glycolic-acid-magnetic-microspheres-prepared-by-rotating-membrane-emulsification-for-transcatheter-arterial-embolization-and-magnetic-ablation-in-vx-2-liver-tumors
#10
Yi-Jun Liang, Hui Yu, Guodong Feng, Linlin Zhuang, Wei Xi, Ming Ma, Jun Chen, Ning Gu, Yu Zhang
Interventional embolization is a popular minimally invasive vascular therapeutic technique and has been widely applied for hepatocellular carcinoma (HCC) therapy. However, harmful effects caused by transcatheter arterial chemoembolization (TACE) and radioembolization, such as the toxicity of chemotherapy or excessive radiation damage, are serious disadvantages and significantly reduce the therapeutic efficacy. Here, a synergistic therapeutic strategy combined transcatheter arterial embolization and magnetic ablation (TAEMA) by using poly(lactic-co-glycolic acid) (PLGA)-magnetic microspheres (MMs) has been successfully applied to orthotopic VX2 liver tumors of rabbits...
December 20, 2017: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/29047408/the-efficacy-of-the-kampo-medicine-rikkunshito-for-chemotherapy-induced-anorexia-rich-trial-study-protocol-for-a-randomized-controlled-trial
#11
Takuya Inoue, Hironori Takagi, Yuki Owada, Yuzuru Watanabe, Takumi Yamaura, Mitsuro Fukuhara, Satoshi Muto, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hiroshi Yokouchi, Kenya Kanazawa, Katsuya Ohbuchi, Takahisa Fukushima, Mitsuru Munakata, Hiroyuki Suzuki
BACKGROUND: Cisplatin is a key drug in lung cancer therapy. However, cisplatin is also well known to induce gastrointestinal disorders, such as chemotherapy-induced nausea and vomiting, anorexia, and weight loss. These symptoms sometimes affect patients' quality of life and make continuation of chemotherapy difficult. Anorexia is a cause of concern for patients with cancer because a persistent loss of appetite progresses to cancer cachexia. Although evidence-based management for chemotherapy has recently been established, there is room for improvement...
October 18, 2017: Trials
https://www.readbyqxmd.com/read/28955007/phase-i-study-of-combined-therapy-with-vorinostat-and-gefitinib-to-treat-bim-deletion-polymorphism-associated-resistance-in-egfr-mutant-lung-cancer-victroy-j-a-study-protocol
#12
Shinji Takeuchi, Kenichi Yoshimura, Tadami Fujiwara, Masahiko Ando, Shinobu Shimizu, Katsuhiko Nagase, Yoshinori Hasegawa, Toshiaki Takahashi, Nobuyuki Katakami, Akira Inoue, Seiji Yano
The BIM deletion polymorphism is reported to be associated with poor outcomes of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) treated with EGFR-TKIs, including gefitinib. We have shown that a histone deacetylase inhibitor, vorinostat, can epigenetically restore BIM function and apoptosis sensitivity to EGFR-TKIs in EGFR-mutant NSCLC cells with BIM deletion polymorphisms. The purpose of this study is to determine the feasibility of combined treatment of vorinostat with gefitinib in BIM deletion polymorphism positive EGFR-mutant NSCLC patients...
2017: Journal of Medical Investigation: JMI
https://www.readbyqxmd.com/read/28955006/phase-i-ii-study-of-alectinib-in-lung-cancer-with-ret-fusion-gene-study-protocol
#13
Shinji Takeuchi, Toshinori Murayama, Kenichi Yoshimura, Takahiro Kawakami, Shizuko Takahara, Yasuhito Imai, Yoshikazu Kuribayashi, Katsuhiko Nagase, Koichi Goto, Makoto Nishio, Yoshinori Hasegawa, Miyako Satouchi, Katsuyuki Kiura, Takashi Seto, Seiji Yano
BACKGROUND: The rearranged during transfection (RET) fusion gene was discovered as a driver oncogene in 1-2% of non-small cell lung cancers (NSCLCs). Alectinib is an approved anaplastic lymphoma kinase (ALK) inhibitor that may also be effective for RET fusion-positive NSCLC. METHODS/DESIGN: RET fusion-positive NSCLC patients treated with at least one regimen of chemotherapy are being recruited. In step 1, alectinib (600 or 450 mg, twice daily) will be administered following a 3+3 design...
2017: Journal of Medical Investigation: JMI
https://www.readbyqxmd.com/read/28934231/principal-component-analysis-identifies-patterns-of-cytokine-expression-in-non-small-cell-lung-cancer-patients-undergoing-definitive-radiation-therapy
#14
Susannah G Ellsworth, Bryan M Rabatic, Jie Chen, Jing Zhao, Jeffrey Campbell, Weili Wang, Wenhu Pi, Paul Stanton, Martha Matuszak, Shruti Jolly, Amy Miller, Feng-Ming Kong
BACKGROUND/PURPOSE: Radiation treatment (RT) stimulates the release of many immunohumoral factors, complicating the identification of clinically significant cytokine expression patterns. This study used principal component analysis (PCA) to analyze cytokines in non-small cell lung cancer (NSCLC) patients undergoing RT and explore differences in changes after hypofractionated stereotactic body radiation therapy (SBRT) and conventionally fractionated RT (CFRT) without or with chemotherapy...
2017: PloS One
https://www.readbyqxmd.com/read/28915900/a-randomized-phase-ii-study-to-assess-the-effect-of-adjuvant-immunotherapy-using-%C3%AE-galcer-pulsed-dendritic-cells-in-the-patients-with-completely-resected-stage-ii-iiia-non-small-cell-lung-cancer-study-protocol-for-a-randomized-controlled-trial
#15
Hideo Saka, Chiyoe Kitagawa, Yukito Ichinose, Mitsuhiro Takenoyama, Hidenori Ibata, Tatsuo Kato, Koji Takami, Motohiro Yamashita, Tadashi Maeda, Sadanori Takeo, Hitoshi Ueda, Kan Okabayashi, Seiji Nagashima, Tadayuki Oka, Hidenori Kouso, Seiichi Fukuyama, Kentaro Yoshimoto, Mototsugu Shimokawa, Akiko M Saito, Suminobu Ito
BACKGROUND: As the toxicity associated with the α-GalCer-pulsed dendritic cell (DC) therapy could be considered to be negligible, its addition to postoperative adjuvant chemotherapy would be expected to greatly improve the therapeutic effect, and could result in prolonged survival. The aim of the present study is to compare the therapeutic efficacy of alpha-galactosylceramide-pulsed DC therapy in patients who have undergone a complete resection of stage II-IIIA non-small-cell lung cancer (NSCLC) followed by postoperative adjuvant therapy with cisplatin plus vinorelbine, to that in patients who did not receive additional treatment (surgical resection plus postoperative adjuvant chemotherapy only)...
September 15, 2017: Trials
https://www.readbyqxmd.com/read/28878202/predicting-organ-specific-risk-interactions-between-radiation-and-chemotherapy-in-secondary-cancer-survivors
#16
Venkata S K Manem, Clemens Grassberger, Harald Paganetti
Several studies have shown that pediatric patients have an increased risk of developing a secondary malignancy several decades after treatment with radiotherapy and chemotherapy. In this work, we use a biologically motivated mathematical formalism to estimate the relative risks of breast, lung and thyroid cancers in childhood cancer survivors due to concurrent therapy regimen. This model specifically includes possible organ-specific interaction between radiotherapy and chemotherapy. The model predicts relative risks for developing secondary cancers after chemotherapy in breast, lung and thyroid tissues, and compared with the epidemiological data...
September 6, 2017: Cancers
https://www.readbyqxmd.com/read/28875225/methodological-quality-evaluation-of-systematic-reviews-or-meta-analyses-on-ercc1-in-non-small-cell-lung-cancer-a-systematic-review
#17
REVIEW
Huan Tao, Yueyuan Zhang, Qian Li, Jin Chen
PURPOSES: To assess the methodological quality of systematic reviews (SRs) or meta-analysis concerning the predictive value of ERCC1 in platinum chemotherapy of non-small cell lung cancer. METHODS: We searched the PubMed, EMbase, Cochrane library, international prospective register of systematic reviews, Chinese BioMedical Literature Database, China National Knowledge Infrastructure, Wan Fang and VIP database for SRs or meta-analysis. The methodological quality of included literatures was evaluated by risk of bias in systematic review (ROBIS) scale...
November 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28866371/no-longer-any-role-for-routine-follow-up-chest-x-rays-in-men-with-stage-i-germ-cell-cancer
#18
MULTICENTER STUDY
H De La Pena, A Sharma, C Glicksman, J Joseph, M Subesinghe, Z Traill, C Verrill, M Sullivan, J Redgwell, E Bataillard, E Pintus, N Dallas, A Gogbashian, M Tuthill, A Protheroe, M Hall
Following radical orchidectomy for testicular cancer, most patients undergo protocolled surveillance to detect tumour recurrences rather than receive adjuvant chemotherapy. Current United Kingdom national and most international guidelines recommend that patients require a chest x-ray (CXR) and serum tumour markers at each follow-up visit as well as regular CT scans; there is however, variation among cancer centres with follow-up protocols. Seminomas often do not cause tumour marker elevation; therefore, CT scans are the main diagnostic tool for detecting relapse...
October 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28865463/carbon-ion-radiotherapy-for-non-small-cell-lung-cancer-with-interstitial-lung-disease-a%C3%A2-retrospective-analysis
#19
Mio Nakajima, Naoyoshi Yamamoto, Kazuhiko Hayashi, Masataka Karube, Daniel K Ebner, Wataru Takahashi, Makoto Anzai, Kenji Tsushima, Yuji Tada, Koichiro Tatsumi, Tadaaiki Miyamoto, Hiroshi Tsuji, Takehiko Fujisawa, Tadashi Kamada
BACKGROUND: Lung cancer is frequently complicated by interstitial lung disease (ILD). Treatment protocols for lung cancer patients with ILD have not been established; surgery, chemotherapy, and radiotherapy can all cause acute exacerbation of ILD. This study evaluated the toxicity and efficacy of carbon ion radiotherapy (CIRT) in patients with non-small cell lung cancer (NSCLC) and ILD. METHODS: Between June 2004 and November 2014, 29 patients diagnosed with NSCLC and ILD were treated with CIRT...
September 2, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28864605/radioembolization-of-colorectal-liver-metastases-indications-technique-and-outcomes
#20
REVIEW
F Edward Boas, Lisa Bodei, Constantinos T Sofocleous
Liver metastases are a major cause of death from colorectal cancer. Intraarterial therapy options for colorectal liver metastases include chemoinfusion via a hepatic arterial pump or port, irinotecan-loaded drug-eluting beads, and radioembolization using 90Y microspheres. Intraarterial therapy allows the delivery of a high dose of chemotherapy or radiation into liver tumors while minimizing the impact on liver parenchyma and avoiding systemic effects. Specificity in intraarterial therapy can be achieved both through preferential arterial flow to the tumor and through selective catheter positioning...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
109129
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"